Washington University School of Medicine
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Washington University School of Medicine sits in the top decile of US sponsors by registered trial count (#12 of 15,742 sponsors by registered trial count).
Washington University School of Medicine: 1,502 sponsored US clinical trials, 214 recruiting.
Washington University School of Medicine sponsors 1,502 registered US clinical trials on ClinicalTrials.gov, 214 of them currently recruiting, and 919 completed. 98 of these trials are in Phase 3-4 (later-stage) and 569 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 20 trials.
Top-decile sponsor footprint
Washington University School of Medicine ranks in the top decile of sponsors by registered trial count (#12 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
919 of 1,159 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,502 total, page 1 of 31
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT07355205
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
NCT06639607
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
NCT07392957
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
NCT07200089
Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients
NCT07313592
Rivastigmine for Antimuscarinic Delirium
NCT06382649
Patient Position Monitoring System for Beam Gated Radiation Therapy of Malignancies of the Chest and Upper Abdomen
NCT07373496
Multicontext Approach for Cognitive Function in Parkinson Disease
NCT07190404
Therapeutic RSK1 Targeting in Myelofibrosis
NCT07379125
5-Fluorouracil Response and Optimization STudy (The FROST Trial)
NCT07419464
Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening
NCT07453459
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
NCT07462507
Vagus Nerve Stimulation for Myelopathy
NCT07660250
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
NCT07126158
CARE Tool Study Aim 3
NCT07296887
Prospective Randomized Trial Comparing Longitudinal vs. Transverse A1 Pulley Release
NCT07516652
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
NCT07107750
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
NCT06904378
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
NCT07200102
Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery
NCT06969287
Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemic Stroke
NCT07404852
Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital
NCT07146568
Remote Ischemic Conditioning for PwSCI
NCT07488793
Healthy Behaviors for Insomnia Prevention in People With HIV and Ongoing Pain
NCT07270406
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
NCT07052305
Health Information for Persons With Spinal Cord Injury
NCT07386522
Cancer Care Companion
NCT07278778
Substance Use in Pregnant People - Optimizing Retention in Treatment
NCT07104123
Spatiotemporal tSCS in Spinal Cord Injury
NCT07397559
CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma
NCT07241117
INCLUDE Program: A Perioperative Wellness Program Tailored for Black Surgical Patients
NCT07283783
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
NCT06968988
Miro3D Randomized Controlled Trial (RCT)
NCT07347106
Tofersen in Non-SOD1 ALS
NCT07294144
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
NCT07226934
Implementation of a Caregiver-Report Suicide-Risk Screener in Children Under Age 8 in a Behavioral Health Center
NCT07350161
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
NCT07155200
Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
NCT06926634
SGLT2 Inhibitors in Geographic Atrophy
NCT07174687
A Digital Intervention to Decrease Self-Stigma Among Pregnant and Postpartum Women With Substance Use Disorder
NCT07211867
Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
NCT06831526
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation
NCT06990711
PET Imaging of MMP Activation in AAA: Clinical Component
NCT07473102
AI-driven Clinical Decision Support for Perioperative Blood Orders
NCT07223853
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
NCT06957431
Suubi4PrEP: Improving PrEP Access and Adherence Among Adolescent Girls and Young Women in Uganda
NCT07002866
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
NCT06795009
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
NCT07092514
Multi-modal Imaging of Myofascial Pain - Phase 2
NCT07322445
Compass 3: A Novel Transition Program to Reduce Disability After Stroke
NCT07069660
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 332 |
| Phase 2 | 237 |
| Phase 3 | 40 |
| Phase 4 | 58 |
Therapeutic Areas
What is open in the Washington University School of Medicine pipeline
214 recruiting of 1,502 indexed (14% open); 919 completed (61%).
Phase mix: 98 late (III/IV) vs 569 early (I/II) (early-phase heavy).
Top condition: Obesity (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Washington University School of Medicine: open-pipeline peers nationwide
Peers matched on 1,502 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Washington University School of Medicine sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,502 trials (± recruiting share)
- Yale University · 1,492 trials · 17% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Washington University School of Medicine page
1,502 registered trials is a research-attention snapshot, not an endorsement of Washington University School of Medicine or any single study.
- 214 of Washington University School of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Washington University School of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Washington University School of Medicine pipeline card: 1,502 registered trials from official public datasets.Report a data error.